The parent GVS-18-B6 lipid was reported as almost completely cleared from mouse liver within 6 hours after IV dosing.
EGFP mRNA LNP; IV; mouse; LC-MS · Figure 2 and text, pp. 10376-10377sales@dcchemicals.com
Lipid GVS-18-B6
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| GVS-18-B6 | 54.6 | Ionizable lipid |
| DSPC | 10.9 | Helper phospholipid |
| Cholesterol | 32.8 | Sterol |
| PEG-conjugated lipid (identity not specified in article) | 1.6 | PEG lipid |
| Reported total | 99.9 | Source values retained |
Formulation calculator unavailable. The reported values total 99.9 mol% because of source rounding; the calculator normalizes them only for weight calculation. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reported89 nmPost-formulation characterizationTable 1, p. 10376
Literature-reported0.06Post-formulation characterizationTable 1, p. 10376
Literature-reported90%Post-formulation characterizationTable 1, p. 10376
Literature-reported6.15TNS binding assayTable 1, p. 10376; TNS method, p. 10382
Literature-reported+2.69 mVPost-formulation characterizationTable 1, p. 10376
Literature-reported+0.98 mVPost-formulation characterizationTable 1, p. 10376
Literature-reported5.30 × 10^7 pg EGFP/g liver24 h after IV administration · 2.56-fold the MC3 value in the same tableTable 1, p. 10376
Literature-reported0.58 × 10^6 pg EGFP/g spleen24 h after IV administrationTable 1, p. 10376
Calculated from literatureApproximately 92:124 h after IV administration · Benchmarks reported at approximately 10:1 to 20:1Calculated from Table 1 values; ratio also stated in text, p. 10377
Literature-reported81 pg/mL6 h after IV administration · MC3: 159 pg/mL in the same tableTable 1 and Figure 2 caption, p. 10376
Additional reported findings
GVS-18-B6 LNPs were reported as well tolerated at doses up to 6 mg/kg, with little elevation in the measured ALT, AST, MCP-1 or IL-6 biomarkers.
Nonstimulatory siRNA LNP; IV; female BALB/c mice · Figure 3 and text, pp. 10377-10378After a 1 mg/kg IV infusion of hOTC mRNA LNP, strong hOTC expression was reported in liver, with substantially lower expression in spleen; the vast majority of GVS-18-B6 was degraded in liver within 24 hours.
hOTC mRNA LNP; 1 mg/kg; 60-minute IV infusion; cynomolgus monkeys · Figure 5A-C and text, pp. 10378-10379Weekly 0.25 mg/kg IV doses for five weeks produced comparable plasma hEPO profiles after doses 1 and 5, with no efficacy pattern indicative of accelerated blood clearance in the reported experiment.
hEPO mRNA LNP; 0.25 mg/kg; IV every 7 days × 5; cynomolgus monkeys · Figure 5D and text, pp. 10378-10379Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetHolland R, Lam K, Jeng S, et al. Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance. ACS Nano. 2024;18:10374-10387. DOI: 10.1021/acsnano.3c09028
Formulation: p. 10375 and Materials & Methods; performance: Table 1 and Figures 2-6.
Formulation: p. 10375 and Materials & Methods; performance: Table 1 and Figures 2-6.